Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of development, including in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease. AR stabilization by androgens makes it distinct from other steroid receptors, which are typically ubiquitinated and degraded by proteasomes after ligand binding. Thus, targeting AR in advanced prostate cancer requires the development of agents that can sustainably degrade variant isoforms for effective therapy. Here we report the discovery and characterization of potent selective AR degraders (SARD) that markedly reduce the activity of wild-type and splice variant isoforms of AR at submicromolar doses. Three SARDs (UT-69, UT-155, and (R)-UT-155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted for degradation previously, with two of these SARD (UT-69 and UT-155) also binding the carboxy-terminal ligand binding domain. Despite different mechanisms of action, all three SARDs degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the approved AR antagonists. Collectively, our results introduce a new candidate class of next-generation therapeutics to manage advanced prostate cancer. Cancer Res; 77(22); 6282–98. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · cited 1×
“expressing PCa have aggressive disease with shorter progression-free- and overall- survival rates and they fail to respond to enzalutamide or abiraterone (16,17).”
BackgroundDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077 · cited 13×
“Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.”
BackgroundInfluentialGuo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
Self-citationActivation of the human androgen receptor through a protein kinase A signaling pathway.
Nazareth, L. V., & Weigel, N. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19900 · Cited by 429 · cited 1×
“Mechanisms attributed to the development of CRPC and resistance to current treatments include over-expression of AR, expression of AR splice variants (AR-SVs) lacking the LBD, mutations in the AR in general but particularly the LBD, over-expression of coactivators and other oncogenic proteins, adrenal or intra-tumoral…”
BackgroundSadar, M. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7777 · Cited by 270 · cited 1×
“Mechanisms attributed to the development of CRPC and resistance to current treatments include over-expression of AR, expression of AR splice variants (AR-SVs) lacking the LBD, mutations in the AR in general but particularly the LBD, over-expression of coactivators and other oncogenic proteins, adrenal or intra-tumoral…”
Background
Cited by
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability
Tsai, J. M., Aguirre, J. D., Li, Y.-D., Brown, J., Focht, V., Kater, L., Kempf, G., Sandoval, B., Schmitt, S., Rutter, J. C., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.06.028 · Cited by 68
Metadata
- Authors
- Ponnusamy, S., Coss, C. C., Thiyagarajan, T., Watts, K., Hwang, D.-J., He, Y., Selth, L. A., McEwan, I. J., Duke, C. B., Pagadala, J., Singh, G., Wake, R. W., Ledbetter, C., Tilley, W. D., Moldoveanu, T., Dalton, J. T., Miller, D. D., & Narayanan, R.
- Venue
- Cancer Research
- Published
- 2017-11-14
- Volume
- 77
- Issue
- 22
- Pages
- 6282-6298
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2760948449
- Cited by
- 90
- References
- 8
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-0976
- The paper
- Ponnusamy, S., Coss, C. C., Thiyagarajan, T., Watts, K., Hwang, D.-J., He, Y., Selth, L. A., McEwan, I. J., Duke, C. B., Pagadala, J., Singh, G., Wake, R. W., Ledbetter, C., Tilley, W. D., Moldoveanu, T., Dalton, J. T., Miller, D. D., & Narayanan, R. (2017). Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-0976
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.